Skye Bioscience (SKYE) Cash from Investing Activities (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Cash from Investing Activities of $10.9 million for Q1 2026, up 185.07% year-over-year from $3.8 million in Q1 2025, and up 488.65% quarter-over-quarter from -$2.8 million in Q4 2025.
Skye Bioscience (SKYE) Cash from Investing Activities (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Cash from Investing Activities for 12 consecutive years, with $10.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 185.07% year-over-year to $10.9 million; the TTM figure through Mar 2026 stood at $4.2 million (up 129.62% YoY), while the FY2025 annual figure was -$19.5 million, down 7839.37% from the prior year.
- Cash from Investing Activities advanced to $10.9 million in Q1 2026 per SKYE's latest filing, from -$2.8 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $10.9 million in Q1 2026 and bottomed at -$12.8 million in Q1 2025.
- Historically, Cash from Investing Activities has averaged $185056.9 across 5 years, with a median of -$4508.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 276758.63% — and 2025, when it slumped 36418.58%.
- Skye Bioscience's Cash from Investing Activities stood at $5.7 million in 2022, then slumped by 100.12% to -$7017.0 in 2023, then soared by 1388.44% to $90410.0 in 2024, then slumped by 3200.88% to -$2.8 million in 2025, then jumped by 488.65% to $10.9 million in 2026.
- Business Quant data shows SKYE's Cash from Investing Activities at $10.9 million in Q1 2026, -$2.8 million in Q4 2025, and $8.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - | 7.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.90 Mn |
| Mar 31, 2026 | 10.90 Mn |
| Dec 31, 2025 | -2.80 Mn |
| Dec 31, 2025 | -2.80 Mn |
| Sep 30, 2025 | 7.97 Mn |
| Sep 30, 2025 | 7.97 Mn |
| Jun 30, 2025 | -11.86 Mn |
| Jun 30, 2025 | -11.86 Mn |
| Mar 31, 2025 | -12.81 Mn |
| Mar 31, 2025 | -12.81 Mn |
| Dec 31, 2024 | 90,410.00 |
| Dec 31, 2024 | 90,410.00 |
| Sep 30, 2024 | -1.45 Mn |
| Sep 30, 2024 | -1.45 Mn |
| Jun 30, 2024 | -32,463.00 |
| Jun 30, 2024 | -32,463.00 |
| Mar 31, 2024 | 1.14 Mn |
| Mar 31, 2024 | 1.14 Mn |
| Dec 31, 2023 | -7,017.00 |
| Dec 31, 2023 | -7,017.00 |